298 related articles for article (PubMed ID: 31828446)
1. A Systems Pharmacology Model for Drug Delivery to Solid Tumors by Antibody-Drug Conjugates: Implications for Bystander Effects.
Burton JK; Bottino D; Secomb TW
AAPS J; 2019 Dec; 22(1):12. PubMed ID: 31828446
[TBL] [Abstract][Full Text] [Related]
2. Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping.
Khera E; Cilliers C; Smith MD; Ganno ML; Lai KC; Keating TA; Kopp A; Nessler I; Abu-Yousif AO; Thurber GM
Neoplasia; 2021 Feb; 23(2):210-221. PubMed ID: 33385970
[TBL] [Abstract][Full Text] [Related]
3. Modeling to capture bystander-killing effect by released payload in target positive tumor cells.
Byun JH; Jung IH
BMC Cancer; 2019 Mar; 19(1):194. PubMed ID: 30832603
[TBL] [Abstract][Full Text] [Related]
4. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.
Singh AP; Sharma S; Shah DK
J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Evaluation of the Effect of Antigen Expression Level on Antibody-Drug Conjugate Exposure in Solid Tumor.
Bussing D; Sharma S; Li Z; Meyer LF; Shah DK
AAPS J; 2021 Apr; 23(3):56. PubMed ID: 33856579
[TBL] [Abstract][Full Text] [Related]
6. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
7. A mechanistic tumor penetration model to guide antibody drug conjugate design.
Vasalou C; Helmlinger G; Gomes B
PLoS One; 2015; 10(3):e0118977. PubMed ID: 25786126
[TBL] [Abstract][Full Text] [Related]
8. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and Pharmacodynamics of TAK-164 Antibody Drug Conjugate Coadministered with Unconjugated Antibody.
Menezes B; Khera E; Calopiz M; Smith MD; Ganno ML; Cilliers C; Abu-Yousif AO; Linderman JJ; Thurber GM
AAPS J; 2022 Oct; 24(6):107. PubMed ID: 36207468
[TBL] [Abstract][Full Text] [Related]
10. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
11. Optimizing Solid Tumor Treatment with Antibody-drug Conjugates Using Agent-Based Modeling: Considering the Role of a Carrier Dose and Payload Class.
Calopiz MC; Linderman JJ; Thurber GM
Pharm Res; 2024 Jun; 41(6):1109-1120. PubMed ID: 38806889
[TBL] [Abstract][Full Text] [Related]
12. Bystander effect of antibody-drug conjugates: fact or fiction?
Giugliano F; Corti C; Tarantino P; Michelini F; Curigliano G
Curr Oncol Rep; 2022 Jul; 24(7):809-817. PubMed ID: 35305211
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
14. A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.
Singh AP; Shah DK
J Pharm Sci; 2019 Jul; 108(7):2465-2475. PubMed ID: 30790581
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic Modeling of Intra-Tumor Spatial Distribution of Antibody-Drug Conjugates: Insights into Dosing Strategies in Oncology.
Weddell J; Chiney MS; Bhatnagar S; Gibbs JP; Shebley M
Clin Transl Sci; 2021 Jan; 14(1):395-404. PubMed ID: 33073529
[TBL] [Abstract][Full Text] [Related]
16. An Agent-Based Systems Pharmacology Model of the Antibody-Drug Conjugate Kadcyla to Predict Efficacy of Different Dosing Regimens.
Menezes B; Cilliers C; Wessler T; Thurber GM; Linderman JJ
AAPS J; 2020 Jan; 22(2):29. PubMed ID: 31942650
[TBL] [Abstract][Full Text] [Related]
17. Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates.
Xu S
Pharm Res; 2015 Nov; 32(11):3577-83. PubMed ID: 26108878
[TBL] [Abstract][Full Text] [Related]
18. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
Shah DK; Haddish-Berhane N; Betts A
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
[TBL] [Abstract][Full Text] [Related]
19. Cellular-Resolution Imaging of Bystander Payload Tissue Penetration from Antibody-Drug Conjugates.
Khera E; Dong S; Huang H; de Bever L; van Delft FL; Thurber GM
Mol Cancer Ther; 2022 Feb; 21(2):310-321. PubMed ID: 34911819
[TBL] [Abstract][Full Text] [Related]
20. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher AH; Brown MP
Br J Cancer; 2017 Dec; 117(12):1736-1742. PubMed ID: 29065110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]